Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Vierboom

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Molecular Immunology|December 1, 1994
Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicityM C Feltkamp, M P Vierboom, W M Kast, et al.
International Journal of Cancer|June 22, 2000
Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTLM P Vierboom, G M Bos, M Ooms, et al.
Annals of the New York Academy of Sciences|July 27, 2000
p53: a potential target antigen for immunotherapy of cancerR Offringa, M P Vierboom, S H van der Burg, et al.
Cancer Research|October 18, 2000
High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, S Zwaveling, Bos GMJ, et al.
Immunology Letters|July 1, 1995
Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilizationM C Feltkamp, M P Vierboom, R E Toes, et al.
Immunology Letters|May 1, 1994
p53, a potential target for tumor-directed T cellsH W Nijman, S H Van der Burg, M P Vierboom, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1993
Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptidesH W Nijman, J G Houbiers, S H van der Burg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 1998
Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitopeM P Vierboom, M C Feltkamp, A Neisig, et al.
Cancer Research|July 29, 1998
Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopesT van Hall, N E van de Rhee, S P Schoenberger, et al.
European Journal of Immunology|September 1, 1995
Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumorsM C Feltkamp, G R Vreugdenhil, M P Vierboom, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Molecular Immunology|December 1, 1994
Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicityM C Feltkamp, M P Vierboom, W M Kast, et al.
International Journal of Cancer|June 22, 2000
Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTLM P Vierboom, G M Bos, M Ooms, et al.
Annals of the New York Academy of Sciences|July 27, 2000
p53: a potential target antigen for immunotherapy of cancerR Offringa, M P Vierboom, S H van der Burg, et al.
Cancer Research|October 18, 2000
High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, S Zwaveling, Bos GMJ, et al.
Immunology Letters|July 1, 1995
Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilizationM C Feltkamp, M P Vierboom, R E Toes, et al.
Immunology Letters|May 1, 1994
p53, a potential target for tumor-directed T cellsH W Nijman, S H Van der Burg, M P Vierboom, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1993
Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptidesH W Nijman, J G Houbiers, S H van der Burg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 1998
Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitopeM P Vierboom, M C Feltkamp, A Neisig, et al.
Cancer Research|July 29, 1998
Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopesT van Hall, N E van de Rhee, S P Schoenberger, et al.
European Journal of Immunology|September 1, 1995
Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumorsM C Feltkamp, G R Vreugdenhil, M P Vierboom, et al.
Pageof 2